Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Major firms rating丨Wedbush: Initiated coverage on Rocket Pharmaceuticals with an "Outperform" rating.
Wedbush initiates coverage of Rocket Pharmaceuticals with an "Outperform" rating and a Target Price of $32. Ongoing pipeline development and internal capacity are expected to support the company's long-term growth potential. (Gelonghui)
Sector Update: Health Care Stocks Softer Late Afternoon
Rocket Pharmaceuticals' Continued Pipeline Development to Support Long-Term Growth Potential, Wedbush Says
Wedbush Starts Rocket Pharmaceuticals With Outperform Into 'Inflection Year'
Wedbush Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $32
